Literature DB >> 14660742

Proinflammatory functions of vascular endothelial growth factor in alloimmunity.

Marlies E J Reinders1, Masayuki Sho, Atsushi Izawa, Ping Wang, Debabrata Mukhopadhyay, Kerith E Koss, Christopher S Geehan, Andrew D Luster, Mohamed H Sayegh, David M Briscoe.   

Abstract

Vascular endothelial growth factor (VEGF), an established angiogenesis factor, is expressed in allografts undergoing rejection, but its function in the rejection process has not been defined. Here, we initially determined that VEGF is functional in the trafficking of human T cells into skin allografts in vivo in the humanized SCID mouse. In vitro, we found that VEGF enhanced endothelial cell expression of the chemokines monocyte chemoattractant protein 1 and IL-8, and in combination with IFN-gamma synergistically induced endothelial cell production of the potent T cell chemoattractant IFN-inducible protein-10 (IP-10). Treatment of BALB/c (H-2d) recipients of fully MHC-mismatched C57BL/6 (H-2b) donor hearts with anti-VEGF markedly inhibited T cell infiltration of allografts and acute rejection. Anti-VEGF failed to inhibit T cell activation responses in vivo, but inhibited intragraft expression of several endothelial cell adhesion molecules and chemokines, including IP-10. In addition, whereas VEGF expression was increased, neovascularization was not associated with acute rejection, and treatment of allograft recipients with the angiogenesis inhibitor endostatin failed to inhibit leukocyte infiltration of the grafts. Thus, VEGF appears to be functional in acute allograft rejection via its effects on leukocyte trafficking. Together, these observations provide mechanistic insight into the proinflammatory function of VEGF in immunity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14660742      PMCID: PMC281640          DOI: 10.1172/JCI17712

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  56 in total

Review 1.  Central role for CD40/CD40 ligand (CD154) interactions in transplant rejection.

Authors:  M D Denton; R M Reul; V R Dharnidharka; J C Fang; P Ganz; D M Briscoe
Journal:  Pediatr Transplant       Date:  1998-02

2.  Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo.

Authors:  K J Kim; B Li; J Winer; M Armanini; N Gillett; H S Phillips; N Ferrara
Journal:  Nature       Date:  1993-04-29       Impact factor: 49.962

3.  Peripheral blood T lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: a potential role for T cells in angiogenesis.

Authors:  M R Freeman; F X Schneck; M L Gagnon; C Corless; S Soker; K Niknejad; G E Peoples; M Klagsbrun
Journal:  Cancer Res       Date:  1995-09-15       Impact factor: 12.701

4.  Human T-cell-mediated destruction of allogeneic dermal microvessels in a severe combined immunodeficient mouse.

Authors:  A G Murray; P Petzelbauer; C C Hughes; J Costa; P Askenase; J S Pober
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-13       Impact factor: 11.205

5.  Serum and platelet-derived growth factor-induced expression of vascular permeability factor mRNA by human vascular smooth muscle cells in vitro.

Authors:  B Williams; A Quinn-Baker; B Gallacher
Journal:  Clin Sci (Lond)       Date:  1995-02       Impact factor: 6.124

6.  Angiotensin II increases vascular permeability factor gene expression by human vascular smooth muscle cells.

Authors:  B Williams; A Q Baker; B Gallacher; D Lodwick
Journal:  Hypertension       Date:  1995-05       Impact factor: 10.190

7.  Stimulation by thyroid-stimulating hormone and Grave's immunoglobulin G of vascular endothelial growth factor mRNA expression in human thyroid follicles in vitro and flt mRNA expression in the rat thyroid in vivo.

Authors:  K Sato; K Yamazaki; K Shizume; Y Kanaji; T Obara; K Ohsumi; H Demura; S Yamaguchi; M Shibuya
Journal:  J Clin Invest       Date:  1995-09       Impact factor: 14.808

8.  Predictive value of inducible endothelial cell adhesion molecule expression for acute rejection of human cardiac allografts.

Authors:  D M Briscoe; A C Yeung; F J Schoen; E N Allred; G Stavrakis; P Ganz; R S Cotran; J S Pober; E L Schoen
Journal:  Transplantation       Date:  1995-01-27       Impact factor: 4.939

9.  Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: implications for tumor angiogenesis.

Authors:  D Shweiki; M Neeman; A Itin; E Keshet
Journal:  Proc Natl Acad Sci U S A       Date:  1995-01-31       Impact factor: 11.205

10.  Endothelial cells modify the costimulatory capacity of transmigrating leukocytes and promote CD28-mediated CD4(+) T cell alloactivation.

Authors:  M D Denton; C S Geehan; S I Alexander; M H Sayegh; D M Briscoe
Journal:  J Exp Med       Date:  1999-08-16       Impact factor: 14.307

View more
  81 in total

1.  Effect of vascular endothelial growth factor and its receptor KDR on the transendothelial migration and local trafficking of human T cells in vitro and in vivo.

Authors:  Monika Edelbauer; Dipak Datta; Ingrid H C Vos; Aninda Basu; Maria P Stack; Marlies E J Reinders; Masayuki Sho; Katiana Calzadilla; Peter Ganz; David M Briscoe
Journal:  Blood       Date:  2010-06-10       Impact factor: 22.113

2.  VEGF blockade inhibits lymphocyte recruitment and ameliorates immune-mediated vascular remodeling.

Authors:  Jiasheng Zhang; Teresa Silva; Timur Yarovinsky; Thomas D Manes; Sina Tavakoli; Lei Nie; George Tellides; Jordan S Pober; Jeffrey R Bender; Mehran M Sadeghi
Journal:  Circ Res       Date:  2010-06-10       Impact factor: 17.367

3.  Netrin-1 Augments Chemokinesis in CD4+ T Cells In Vitro and Elicits a Proinflammatory Response In Vivo.

Authors:  Leo Boneschansker; Hironao Nakayama; Michele Eisenga; Johannes Wedel; Michael Klagsbrun; Daniel Irimia; David M Briscoe
Journal:  J Immunol       Date:  2016-07-18       Impact factor: 5.422

4.  Vascular endothelial growth factor antagonist modulates leukocyte trafficking and protects mouse livers against ischemia/reperfusion injury.

Authors:  Sei-ichiro Tsuchihashi; Bibo Ke; Fady Kaldas; Evelyn Flynn; Ronald W Busuttil; David M Briscoe; Jerzy W Kupiec-Weglinski
Journal:  Am J Pathol       Date:  2006-02       Impact factor: 4.307

5.  Every allograft needs a silver lining.

Authors:  Alan G Contreras; David M Briscoe
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

Review 6.  Biocompatible materials for continuous glucose monitoring devices.

Authors:  Scott P Nichols; Ahyeon Koh; Wesley L Storm; Jae Ho Shin; Mark H Schoenfisch
Journal:  Chem Rev       Date:  2013-02-07       Impact factor: 60.622

7.  Maintenance of airway epithelium in acutely rejected orthotopic vascularized mouse lung transplants.

Authors:  Mikio Okazaki; Andrew E Gelman; Jeremy R Tietjens; Aida Ibricevic; Christopher G Kornfeld; Howard J Huang; Steven B Richardson; Jiaming Lai; Joel R Garbow; G Alexander Patterson; Alexander S Krupnick; Steven L Brody; Daniel Kreisel
Journal:  Am J Respir Cell Mol Biol       Date:  2007-08-23       Impact factor: 6.914

8.  Cutting edge: Vascular endothelial growth factor-mediated signaling in human CD45RO+ CD4+ T cells promotes Akt and ERK activation and costimulates IFN-gamma production.

Authors:  Aninda Basu; Andre Hoerning; Dipak Datta; Monika Edelbauer; Maria P Stack; Katiana Calzadilla; Soumitro Pal; David M Briscoe
Journal:  J Immunol       Date:  2009-12-11       Impact factor: 5.422

Review 9.  Angiogenesis and hypoxia in the kidney.

Authors:  Tetsuhiro Tanaka; Masaomi Nangaku
Journal:  Nat Rev Nephrol       Date:  2013-03-05       Impact factor: 28.314

10.  Calcineurin inhibitors augment endothelial-to-mesenchymal transition by enhancing proliferation in association with cytokine-mediated activation.

Authors:  Craig B Woda; Sarah Bruneau; Anne Linde Mak; Zdenka Haskova; Kaifeng Liu; Chandra C Ghosh; David M Briscoe
Journal:  Biochem Biophys Res Commun       Date:  2019-09-18       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.